In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 EPS ...

TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...

Investing.com -- Damora Therapeutics Inc (NASDAQ:DMRA) shares jumped 15.5% Monday following the announcement of Jennifer ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead ...

Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic ...

Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic ...

Pfizer Inc. announced positive topline results from the phase 3 TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose ...

News, features, and commentary about cancer-related issues ...

Phase 3 TALAPRO-3 results show that talazoparib plus enzalutamide significantly improves radiographic progression-free ...